Feasibility Study of Adjuvant Chemotherapy of S-1 and Carboplatin for Completely Resected Non-Small Cell Lung Cancer

Background: The purpose of this study was to evaluate the feasibility and compliance of adjuvant chemotherapy of S-1 plus carboplatin for patients with completely resected non-small cell lung cancer (NSCLC) of pathological stage IB-IIIB. Methods: S-1 was given orally at a dose of 80 mg/m(2)/day for 2 weeks, followed by a 2-week period of no treatment. Carboplatin was given intravenously on day 8 at an area under the curve of 6. This regimen was repeated for four to six 28-day courses. Results: Seventeen patients were enrolled in this study. Fourteen of them completed at least 4 cycles of chemotherapy. Nine patients had grade 2 and three patients had grade 3 thrombocytopenia, respectively. Severe nonhematologic toxicities were uncommon. Treatment was delayed in a few patients because of prolonged thrombocytopenia. Conclusion: We concluded that the regimen was feasible and tolerable for patients with completely resected NSCLC as adjuvant chemotherapy. Copyright (c) 2013 S. Karger AG, Basel